ADAURA研究中的术后化疗使用与转归:奥希替尼作为切除后EGFR突变NSCLC的辅助治疗
ADAURA研究纳入682例切除后IB-IIIA期EGFR突变NSCLC患者,随机接受奥希替尼或安慰剂3年;60%患者接受过辅助化疗(中位4.0周期)。无论是否接受辅助化疗,奥希替尼较安慰剂均显示无病生存获益(HR=0.16 vs HR=0.23),支持奥希替尼作为术后辅助治疗。
要点
- 682例中410例(60%)接受辅助化疗,奥希替尼组203例、安慰剂组207例,中位4.0周期。
- 接受辅助化疗者DFS HR=0.16(95%CI 0.10-0.26),未接受者HR=0.23(95%CI 0.13-0.40)。
- 奥希替尼在IB-IIIA期各疾病分期中均显示DFS获益,无论是否接受过辅助化疗。
核心结论
- 研究结果支持奥希替尼作为IB-IIIA期EGFR突变NSCLC患者切除后的有效治疗,无论此前是否接受过辅助化疗。
研究设计与样本
- 3期ADAURA研究(NCT02511106),将切除后IB-IIIA期EGFR突变NSCLC患者按1:1随机分配接受奥希替尼或安慰剂治疗3年。
- 辅助化疗在随机化前非强制,由医生和患者选择;总人群(IB-IIIA期)中接受与未接受辅助化疗的DFS为预设分析。
- 探索性分析包括:按患者年龄、疾病分期和地理区域分析辅助化疗使用情况;按辅助化疗使用和疾病分期分析DFS。
主要发现
- 682例中410例(60%)接受辅助化疗(奥希替尼组203例,安慰剂组207例),中位持续4.0周期。
- 辅助化疗使用频率:年龄<70岁338/509(66%)vs ≥70岁72/173(42%);II-IIIA期352/466(76%)vs IB期57/216(26%);亚洲入组268/414(65%)vs 亚洲以外142/268(53%)。
- 接受辅助化疗者中奥希替尼较安慰剂DFS HR=0.16(95%CI 0.10-0.26),未接受辅助化疗者HR=0.23(95%CI 0.13-0.40),无论疾病分期。
临床怎么用
- 作者结论认为,研究结果支持奥希替尼作为IB-IIIA期EGFR突变NSCLC患者切除后的有效治疗,无论此前是否接受过辅助化疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant chemotherapy use and outcomes from ADAURA. METHODS: Patients with resected stages IB to IIIA EGFRm NSCLC were randomized 1:1 to receive osimertinib or placebo for 3 years. Adjuvant chemotherapy before randomization was not mandatory, per physician and patient choice. DFS in the overall population (IB-IIIA), with and without adjuvant chemotherapy, was a prespecified analysis. Exploratory analyses included the following: adjuvant chemotherapy use by patient age, disease stage, and geographic location; DFS by adjuvant chemotherapy use and disease stage. RESULTS: Overall, 410 of 682 patients (60%) received adjuvant chemotherapy (osimertinib, n = 203; placebo, n = 207) for a median duration of 4.0 cycles. Adjuvant chemotherapy use was more frequent in patients: aged less than 70 years (338 of 509; 66%) versus more than or equal to 70 years (72 of 173; 42%); with stages II to IIIA (352 of 466; 76%) versus stage IB (57 of 216; 26%); and enrolled in Asia (268 of 414; 65%) versus outside of Asia (142 of 268; 53%). A DFS benefit favoring osimertinib versus placebo was observed in patients with (DFS hazard ratio = 0.16, 95% confidence interval: 0.10-0.26) and without adjuvant chemotherapy (hazard ratio = 0.23, 95% confidence interval: 0.13-0.40), regardless of disease stage. CONCLUSIONS: These findings support adjuvant osimertinib as an effective treatment for patients with stages IB to IIIA EGFRm NSCLC after resection, with or without previous adjuvant chemotherapy.
引用
- Wu YL, John T, Grohe C, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. J Thorac Oncol. 2021. PMID: 34740861. doi:10.1016/j.jtho.2021.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。